Blood biomarker for diagnosis, prognosis prediction, or treatment of parkinson’s disease, method for diagnosing parkinson’s disease, or predicting prognosis using the same, and method for screening substances for treating parkinson’s disease

A method comprising the steps of:

• (S1) measuring the level of any one or more of miRNAs selected from the group consisting of hsa-miR-11401, has-miR-12136, hsa-miR-145-3p, hsa-miR-2115-3p, hsa-miR-23a-3p, hsa-miR-27a-3p, hsa-miR-28-3p, hsa-miR-331-3p, hsa-miR-4435, hsa-miR-4507, hsa-miR-4685-3p, hsa-miR-501-3p, hsa-miR-618, and hsa-miR-7109-3p in a biological sample isolated from a subject;
• (S2) comparing the level of the miRNA with the level of the miRNA in a biological sample isolated from a normal control group;
• (S3) diagnosing a subject as having PD, when among the miRNAs in a biological sample isolated from the subject:
• (a) the level of one or more of miRNAs selected from the group consisting of hsa-miR-11401, hsa-miR-28-3p, hsa-miR-331-3p, hsa-miR-4435, hsa-miR-4685-3p, and hsa-miR-501-3p is more than 2 fold change increase compared to the level of the miRNAs in a biological sample isolated from a normal control group, and the AUC value is ≥0.5, the p-value is <0.5, the Confidence Limits value falls between 0.001 and 165;
• or
• (b) the level of one or more of miRNAs selected from the group consisting of hsa-miR-145-3p, hsa-miR-23a-3p, hsa-miR-27a-3p, and hsa-miR-618 is more than 2 fold change decreased compared to the level of the miRNAs in a biological sample isolated from a normal control group, and the AUC value is ≥0.5, the p-value is <0.5, the Confidence Limits value falls between 0.001 and 165;
• and
• (S4) treating the PD with chemotherapy, surgery, or biological therapy when PD is diagnosed in step (S3).